NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME
申请人:Gu Yu Gui
公开号:US20070225332A1
公开(公告)日:2007-09-27
The present invention relates to compounds of formula (I),
which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.
Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
申请人:Gu Yu Gui
公开号:US08748627B2
公开(公告)日:2014-06-10
The present invention relates to compounds of formula (I),
which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.
Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis
作者:Gerardo D. Francisco、Zhong Li、J.Donald Albright、Nancy H. Eudy、Alan H. Katz、Peter J. Petersen、Pornpen Labthavikul、Guy Singh、Youjun Yang、Beth A. Rasmussen、Yang-I Lin、Tarek S. Mansour
DOI:10.1016/j.bmcl.2003.09.082
日期:2004.1
Over 50 phenyl thiazolyl urea and carbamate derivatives were synthesized for evaluation as new inhibitors of bacterial cell-wall biosynthesis. Many of them demonstrated good activity against MurA and MurB and gram-positive bacteria including MRSA, VRE and PRSP. 3,4-Difluorophenyl 5-cyanothiazolylurea (3p) with clog P of 2.64 demonstrated antibacterial activity against both gram-positive and gram-negative bacteria. (C) 2003 Elsevier Ltd. All rights reserved.